For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...

Coupled with TNBC's aggressive biology, high rate of early recurrence, and tendency to metastasize to vital organs like the ...

While radiation therapy is an effective tool to destroy cancer cells, a new study from Vanderbilt researchers suggests that in an aggressive form of breast cancer, it may also trigger a protective ...

Ultrasensitive circulating tumor DNA (ctDNA) testing may help identify women with triple-negative breast cancer who are at either a very high or very low risk for recurrence after surgery, new ...

Patients with triple-negative breast cancer (TNBC) often have a poor prognosis. Existing staging systems cannot accurately assess patients’ recurrence risk, due to the tumor’s significant ...

Precision DC: Personalized neoantigen dendritic cell vaccine pilot trial for high-risk triple-negative breast cancer after neoadjuvant therapy. This is an ASCO Meeting Abstract from the 2026 ASCO ...

A global, multicenter phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National Cancer Centre Singapore, has demonstrated a significant breakthrough in ...

Hearing the words "triple-negative breast cancer" (TNBC) can be overwhelming. It's a diagnosis that sounds heavy — not just because breast cancer itself is frightening, but because this particular ...

A new study has revealed a promising new approach to curb the spread of triple‑negative breast cancer, one of the most aggressive and difficult‑to‑treat forms of the disease. Published recently in ...

While triple-negative breast cancer (TNBC) is generally an aggressive subtype, it is highly heterogeneous, with a subset of patients having a more favorable biology and high responsiveness to systemic ...

The treatment landscape for patients with triple-negative breast cancer (TNBC) has evolved significantly in recent years, driven by the broader use of neoadjuvant therapy and the adaptation of ...

The treatment landscape for these patients is evolving ...